<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304096</url>
  </required_header>
  <id_info>
    <org_study_id>11992</org_study_id>
    <secondary_id>UVACC-BREAST-34</secondary_id>
    <secondary_id>UVACC-HIT-032.7</secondary_id>
    <secondary_id>UVACC-PRC-366-05</secondary_id>
    <secondary_id>UVACC-GCRC-DRB001</secondary_id>
    <nct_id>NCT00304096</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer</brief_title>
  <official_title>Evaluation of the Safety and Immunogenicity of Vaccination With Multiple Synthetic Peptides in Participants With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an effective immune response
      to kill tumor cells. Giving booster vaccinations may make a stronger immune response and
      kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating
      patients with stage III or stage IV breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the safety of a vaccine comprising multiple synthetic breast
           cancer-associated peptides and a tetanus toxoid helper peptide emulsified in Montanide
           ISA-51 in patients with stage III or IV adenocarcinoma of the breast.

        -  Determine, preliminarily, the frequency of immune responses against the 9 class I
           MHC-restricted peptides in patients treated with the vaccine.

        -  Determine, preliminarily, the cytotoxic responses of T-cells to allogeneic breast
           cancer cells and autologous breast cancer cells (when available).

      OUTLINE: This is an open-label study.

      Patients receive peptide vaccine comprising 9 synthetic breast cancer peptides and tetanus
      toxoid helper peptide emulsified in Montanide ISA-51 subcutaneously and intradermally once
      daily on days 1, 8, 15, 36, 57, and 78 in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed every 3 months for 1 year.

      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Number of Participants Who Experienced Dose-limiting Adverse Events</measure>
    <time_frame>30 days post administration of last vaccine</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety of the 9-peptide mixture if fewer than 33% of patients experience a dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With T-cell Responses Against the Vaccine as Measured by Elispot Assay After 14 Day in Vitro Sensitization</measure>
    <time_frame>Days 1-78</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Stratum 1: Receiving Hormone Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with 9 peptide vaccine who received hormone therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2: Not receiving hormone therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving 9 peptide vaccine who did not receive hormone therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine</intervention_name>
    <arm_group_label>Stratum 1: Receiving Hormone Therapy</arm_group_label>
    <arm_group_label>Stratum 2: Not receiving hormone therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the breast

               -  Stage III or IV disease

               -  Primary or recurrent disease

               -  Invasive lobular carcinoma allowed

          -  HLA-A1, -A2, -A3, or -A31 positive

          -  Underwent and recovered from prior primary therapy

               -  Patients with no clinical or radiological evidence of disease who had a previous
                  diagnosis of stage III or IV breast cancer must have undergone prior
                  antineoplastic therapy including, but not limited to, surgery, chemotherapy, and
                  radiotherapy within the past 36 months

          -  Must have at least one undissected axillary and/or inguinal lymph node basin

          -  No history of brain metastases

          -  Hormone receptor status

               -  Estrogen receptor-positive or -negative tumor

        PATIENT CHARACTERISTICS:

          -  ECOG performance status of 0 or 1

          -  Body weight &gt; 110 lbs (without clothes)

          -  Male or female

          -  Menopausal status not specified

          -  Absolute neutrophil count &gt; 1000/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Hemoglobin &gt; 9 g/dL

          -  Hemoglobin A1c &lt; 7%

          -  AST and ALT ≤ 2.5 x upper limit of normal (ULN)

          -  Bilirubin ≤ 2.5 x ULN

          -  Alkaline phosphatase ≤ 2.5 x ULN

          -  Creatinine ≤ 1.5 x ULN

          -  HIV negative

          -  Hepatitis C negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known or suspected allergies to any component of the vaccine

          -  No active infection requiring antibiotics

          -  No New York Heart Association class III or IV heart disease

          -  No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or
             autoimmune disorders with visceral involvement, except the following:

               -  Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without
                  symptoms

               -  Clinical evidence of vitiligo

               -  Other forms of depigmenting illness

               -  Mild arthritis requiring nonsteroidal antiinflammatory drugs

          -  No medical contraindication or potential problem that would preclude study
             participation

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior surgery

          -  More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy

          -  More than 4 weeks since prior and no concurrent allergy desensitization injections

          -  More than 4 weeks since prior parenteral, oral, or inhaled corticosteroids

               -  No concurrent inhaled steroids (e.g., Advair® or triamcinolone acetonide)

               -  Prior or concurrent topical corticosteroids allowed

          -  More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa,
             darbepoetin alfa, or pegfilgrastim)

          -  More than 4 weeks since prior and no concurrent other investigational medication

          -  More than 4 weeks since prior and no concurrent other agents with putative
             immunomodulating activity except for non-steroidal anti-inflammatory agents

          -  Prior and concurrent hormonal therapy (e.g., tamoxifen, raloxifene, toremifene,
             fulvestrant, letrozole, anastrozole, or exemestane) allowed

          -  No prior vaccination with any synthetic peptides in this protocol

               -  Vaccines for infectious disease (e.g., influenza) allowed, provided they are
                  administered ≥ 2 weeks prior to or ≥ 2 weeks after study vaccine

          -  Short term therapy for acute conditions not related to breast cancer allowed

          -  No concurrent illegal drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Brenin, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 26, 2013</lastchanged_date>
  <firstreceived_date>March 15, 2006</firstreceived_date>
  <firstreceived_results_date>January 15, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>invasive lobular breast carcinoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>University of Virginia Dec 13, 2005 to May 6, 2008</recruitment_details>
      <pre_assignment_details>12 participants were registered to the study and 11 received vaccines. One participant was not compliant and did not receive vaccine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stratum 1: Received Hormonal Therapy</title>
          <description>Participants received hormonal therapy</description>
        </group>
        <group group_id="P2">
          <title>Stratum 2: Had Not Received Hormonal Therapy</title>
          <description>Participants had not received hormonal therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5">6 patients enrolled, 1 not treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stratum 1: Received Hormonal Therapy</title>
          <description>Participants received hormonal therapy</description>
        </group>
        <group group_id="B2">
          <title>Stratum 2: Had Not Received Hormonal Therapy</title>
          <description>Participants had not received hormonal therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.7" spread="5.75"/>
                <measurement group_id="B2" value="59.6" spread="14.47"/>
                <measurement group_id="B3" value="58.0" spread="10.13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Experienced Dose-limiting Adverse Events</title>
        <description>Safety of the 9-peptide mixture if fewer than 33% of patients experience a dose-limiting toxicity</description>
        <time_frame>30 days post administration of last vaccine</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1: Received Hormonal Therapy</title>
            <description>Participants received hormonal therapy</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2: Had Not Received Hormonal Therapy</title>
            <description>Participants had not received hormonal therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Participants Who Experienced Dose-limiting Adverse Events</title>
            <description>Safety of the 9-peptide mixture if fewer than 33% of patients experience a dose-limiting toxicity</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With T-cell Responses Against the Vaccine as Measured by Elispot Assay After 14 Day in Vitro Sensitization</title>
        <time_frame>Days 1-78</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1: Received Hormonal Therapy</title>
            <description>Participants received hormonal therapy</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2: Had Not Received Hormonal Therapy</title>
            <description>Participants had not received hormonal therapy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Participants With T-cell Responses Against the Vaccine as Measured by Elispot Assay After 14 Day in Vitro Sensitization</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days post last vaccine</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stratum 1: Received Hormonal Therapy</title>
          <description>Participants received hormonal therapy</description>
        </group>
        <group group_id="E2">
          <title>Stratum 2: Had Not Received Hormonal Therapy</title>
          <description>Participants had not received hormonal therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3 fatigue was an expected event.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain, headache</sub_title>
                <description>Grade 3 headache was an expected event.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Bullock, PhD and David Brenin, MD</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-924-0180</phone>
      <email>kb9d@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
